Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced positive results from the diagnostic Phase 2 DISCO study with 64Cu-SARTATE in patients with known or suspected neuroendocrine tumours. …
Latest Video
New Stories
-
The Dispatched Podcast - 6 June
June 6, 2025 - - Podcast -
Health department amends published blood review information
June 5, 2025 - - Latest News -
'My experience was awful, I really had to fight to be taken seriously and advocate for myself'
June 5, 2025 - - Latest News -
UK moves to pricing changes as Australian-based companies baulk at listings
June 5, 2025 - - Latest News -
Clarity announces positive top-line results from DISCO trial
June 5, 2025 - - Australian Biotech -
Clinical trial success kicks off $5m fund-raising round for WA’s Lixa
June 5, 2025 - - Australian Biotech -
Wesfarmers Health acquires Pharmacy 4 Less group
June 4, 2025 - - Latest News